Heron Therapeutics (NASDAQ:HRTX - Get Free Report) was downgraded by research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued to investors on Tuesday.
Separately, Needham & Company LLC reissued a "buy" rating and set a $4.00 price objective on shares of Heron Therapeutics in a report on Wednesday, December 4th.
Read Our Latest Research Report on Heron Therapeutics
Heron Therapeutics Stock Performance
Heron Therapeutics stock traded up $0.02 during midday trading on Tuesday, reaching $1.53. 1,685,491 shares of the stock were exchanged, compared to its average volume of 2,683,605. The company's fifty day moving average is $1.53 and its 200-day moving average is $2.11. Heron Therapeutics has a 52 week low of $1.04 and a 52 week high of $3.93. The firm has a market cap of $232.71 million, a PE ratio of -8.50 and a beta of 1.67.
Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). The business had revenue of $32.81 million during the quarter, compared to analysts' expectations of $36.40 million. During the same quarter last year, the business posted ($0.17) EPS. On average, sell-side analysts anticipate that Heron Therapeutics will post -0.13 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. nVerses Capital LLC bought a new position in shares of Heron Therapeutics during the second quarter valued at approximately $27,000. B. Riley Wealth Advisors Inc. bought a new position in Heron Therapeutics in the 2nd quarter worth $41,000. Sei Investments Co. purchased a new stake in shares of Heron Therapeutics in the 2nd quarter worth about $44,000. E Fund Management Co. Ltd. bought a new stake in shares of Heron Therapeutics during the 2nd quarter valued at about $55,000. Finally, Cutter & CO Brokerage Inc. bought a new stake in shares of Heron Therapeutics during the 3rd quarter valued at about $39,000. Institutional investors own 80.01% of the company's stock.
About Heron Therapeutics
(
Get Free Report)
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Articles
Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
